We have located links that may give you full text access.
Efficacy of Ethanolamine Oleate Sclerotherapy in Treatment of Peripheral Giant Cell Granuloma.
Journal of Oral and Maxillofacial Surgery 2016 November
PURPOSE: The aim of this study was to evaluate the efficacy of ethanolamine oleate (EO) sclerotherapy in the treatment of peripheral giant cell granuloma.
PATIENTS AND METHODS: This study included 24 patients presenting with PGCGs greater than 2 cm in diameter. Definitive diagnosis was confirmed after histopathologic examination of incisional biopsy specimens. EO sclerotherapy at a concentration of 2.5% was injected into each lesion once a week. Repeated injections were performed if needed. The treatment response was recorded as complete remission, moderate response, or no change.
RESULTS: This study involved 11 male and 13 female patients, ranging in age from 9 to 70 years; the average age was 45.3 years. The mandible (75%) was involved more than the maxilla. PGCGs occurred posteriorly (62.5%) more than anteriorly. The number of injection sessions was 57, with an average of 2.4 sessions per lesion. Clinical improvement was seen in 23 patients: complete remission in 20 (83.3%) and moderate improvement in 3 (12.5%). No clinical improvement occurred in 1 patient (4.2%).
CONCLUSIONS: EO injection offers an alternative to conventional methods for the treatment of PGCG. The technique is straightforward, safe, and cost-effective with a high success rate.
PATIENTS AND METHODS: This study included 24 patients presenting with PGCGs greater than 2 cm in diameter. Definitive diagnosis was confirmed after histopathologic examination of incisional biopsy specimens. EO sclerotherapy at a concentration of 2.5% was injected into each lesion once a week. Repeated injections were performed if needed. The treatment response was recorded as complete remission, moderate response, or no change.
RESULTS: This study involved 11 male and 13 female patients, ranging in age from 9 to 70 years; the average age was 45.3 years. The mandible (75%) was involved more than the maxilla. PGCGs occurred posteriorly (62.5%) more than anteriorly. The number of injection sessions was 57, with an average of 2.4 sessions per lesion. Clinical improvement was seen in 23 patients: complete remission in 20 (83.3%) and moderate improvement in 3 (12.5%). No clinical improvement occurred in 1 patient (4.2%).
CONCLUSIONS: EO injection offers an alternative to conventional methods for the treatment of PGCG. The technique is straightforward, safe, and cost-effective with a high success rate.
Full text links
Get seemless 1-tap access through your institution/university
For the best experience, use the Read mobile app
All material on this website is protected by copyright, Copyright © 1994-2024 by WebMD LLC.
This website also contains material copyrighted by 3rd parties.
By using this service, you agree to our terms of use and privacy policy.
Your Privacy Choices
You can now claim free CME credits for this literature searchClaim now
Get seemless 1-tap access through your institution/university
For the best experience, use the Read mobile app